A First-in-Human, Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single-Induction Dose of convertibleCAR™-T Cells Armed with MicAbody™ Protein (ASP2802) Followed by Maintenance Booster Doses of the MicAbody Protein in Patients with CD20-Positive Relapsed or Refractory B-Cell Lymphomas

  • Wong, Shu (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

Effective start/end date20/03/2419/03/26


  • Clinical Trials
  • 2802-CL-0101